Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04999202
Title A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

lung non-small cell carcinoma

head and neck squamous cell carcinoma

transitional cell carcinoma

Advanced Solid Tumor

Therapies

BAY2416964 + Pembrolizumab

BAY2416964

Age Groups: adult | senior
Covered Countries USA | ITA


No variant requirements are available.